Inovio Pharmaceuticals spinoff Geneos Therapeutics will put the proceeds from the series A1 round towards advancing its liver cancer vaccine candidate.

Echo Health Ventures and Humana have returned to back the healthcare delivery provider’s series D round, which valued it at $1.7bn.

The Pfizer and Johnson & Johnson-backed cancer treatment developer is eyeing expansion in Asia after receiving $40m in additional series D funding.

An unnamed care provider has added $20m to the $80m the software-based therapeutics developer received from investors including Novartis and SoftBank in December.

Access Biotechnology and returning investor Eli Lilly were among the participants in a series B round for the RNA-based drug developer.

Susquehanna International Group looks set to exit the microbiome therapeutics developer, which has filed to raise up to $100m in its initial public offering.

Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.

Nationwide Ventures co-led a $15m series B round for the health data platform developer that included Aflac Corporate Ventures and Epsilon Health Investors.

LabCorp Venture Fund, Bristol Myers Squibb and Takeda Ventures contributed to $7m in equity funding and a $6m convertible note for the cancer drug developer.

Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.